English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#cholangiocarcinoma search results

BasGrootKoerkam's profile picture. HPB-transplant surgeon
Bas Groot Koerkamp
 @BasGrootKoerkam
Oct 3

Primary percutaneous stenting for malignant hilar biliary obstruction. No longer cholangitis or pancreatitis keeping you from systemic treatment. #cholangiocarcinoma #drainage authors.elsevier.com/sd/article/S25…

BasGrootKoerkam's tweet image. Primary percutaneous stenting for malignant hilar biliary obstruction. No longer cholangitis or pancreatitis keeping you from systemic treatment. #cholangiocarcinoma #drainage authors.elsevier.com/sd/article/S25…
1
16
42
11
4K
BeauToskichMD's profile picture. Professor of Radiology, Director of Interventional Oncology, Mayo Clinic Florida. Views are my own.
Beau Bosko Toskich, MD FSIR
@BeauToskichMD
Oct 24

Unresectable intrahepatic #cholangiocarcinoma conversion/transplantation is our #1 MDT mission. 🤝 This evidence is so welcome. ✨ Inadequate FLR, tumor response, and biological test-of-time are addressed with neoadjuvant #Y90 radiation lobectomy. 🌳 We are exploring this…

BeauToskichMD's tweet image. Unresectable intrahepatic #cholangiocarcinoma conversion/transplantation is our #1 MDT mission. 🤝 This evidence is so welcome. ✨ Inadequate FLR, tumor response, and biological test-of-time are addressed with neoadjuvant #Y90 radiation lobectomy. 🌳 We are exploring this…
BeauToskichMD's tweet image. Unresectable intrahepatic #cholangiocarcinoma conversion/transplantation is our #1 MDT mission. 🤝 This evidence is so welcome. ✨ Inadequate FLR, tumor response, and biological test-of-time are addressed with neoadjuvant #Y90 radiation lobectomy. 🌳 We are exploring this…
BeauToskichMD's tweet image. Unresectable intrahepatic #cholangiocarcinoma conversion/transplantation is our #1 MDT mission. 🤝 This evidence is so welcome. ✨ Inadequate FLR, tumor response, and biological test-of-time are addressed with neoadjuvant #Y90 radiation lobectomy. 🌳 We are exploring this…
FlavioRochaMD's profile picture. Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute 🇺🇸 🇧🇷 in #PDX #PNW 🏔️ 🌲 🌊 ASCO FCOI: https://t.co/8W15jPkVs7
Flavio G Rocha, MD, FACS, FSSO
 @FlavioRochaMD
Oct 24

Real world 🌎 #NEOGAP #cholangiocarcinoma @OHSUKnight @curecc @c3_cholangio 💚

0
3
16
1
5K
1
6
50
5
4K
SewantiLimaye's profile picture. Director Medical&Precision Oncology #precisiononcology #liquidbx #hnc #LCSM @DanaFarber @Harvard @ColumbiaMed @JIPOEditors @rfhospital #IMPACTIndia
Sewanti Limaye 🇮🇳🇺🇸
 @SewantiLimaye
Dec 11

Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care

SewantiLimaye's tweet image. Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care
SewantiLimaye's tweet image. Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care
SewantiLimaye's tweet image. Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care
SewantiLimaye's tweet image. Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care
JavleMilind's profile picture. Hubert L and Olive Stringer Professor GI Medical Oncology and Attending Physician, MD Anderson Cancer Center Chair, NCI Task Force Hepatobiliary Cancers
Milind Javle
 @JavleMilind
Dec 10

Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas

JavleMilind's tweet image. Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas
JavleMilind's tweet image. Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas
JavleMilind's tweet image. Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas
JavleMilind's tweet image. Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas
0
4
22
0
3K
0
2
15
0
731
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Nov 4

🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]

HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
0
5
24
7
2K
MarioBalsaMD's profile picture. Medical Oncology resident at @ICO_oncologia | Currently Rotation Resident Research at @MDAndersonNews 🇺🇸 | @OncoAlert team 💥 #OncoAlertAF | Pianist 🎹
Mario Balsa
@MarioBalsaMD
Oct 20

🚨#ESMO25 #Cholangiocarcinoma –Phase 2–3 ZSAB-neoGOLP trial (Toripalimab + Lenvatinib + GEMOX) in resectable high-risk iCCA 🎯 mEFS 18.0 vs 8.7 mo 💥 ORR 54.4% | MPR 19.3% | pCR 4.5% ✨ OS trend favoring neoadjuvant arm (NE vs 31.4 mo) A strong neoadjuvant signal! Sometimes the…

MarioBalsaMD's tweet image. 🚨#ESMO25 #Cholangiocarcinoma –Phase 2–3 ZSAB-neoGOLP trial (Toripalimab + Lenvatinib + GEMOX) in resectable high-risk iCCA 🎯 mEFS 18.0 vs 8.7 mo 💥 ORR 54.4% | MPR 19.3% | pCR 4.5% ✨ OS trend favoring neoadjuvant arm (NE vs 31.4 mo) A strong neoadjuvant signal! Sometimes the…
MarioBalsaMD's tweet image. 🚨#ESMO25 #Cholangiocarcinoma –Phase 2–3 ZSAB-neoGOLP trial (Toripalimab + Lenvatinib + GEMOX) in resectable high-risk iCCA 🎯 mEFS 18.0 vs 8.7 mo 💥 ORR 54.4% | MPR 19.3% | pCR 4.5% ✨ OS trend favoring neoadjuvant arm (NE vs 31.4 mo) A strong neoadjuvant signal! Sometimes the…
MarioBalsaMD's tweet image. 🚨#ESMO25 #Cholangiocarcinoma –Phase 2–3 ZSAB-neoGOLP trial (Toripalimab + Lenvatinib + GEMOX) in resectable high-risk iCCA 🎯 mEFS 18.0 vs 8.7 mo 💥 ORR 54.4% | MPR 19.3% | pCR 4.5% ✨ OS trend favoring neoadjuvant arm (NE vs 31.4 mo) A strong neoadjuvant signal! Sometimes the…
0
15
32
10
2K
DeCarlis_R's profile picture. 🇮🇹 HPB & Transplant Surgeon (liver/kidney/pancreas). Laparoscopy & robot. DCD & machine perfusion. Fond of my job. Tweets are my own.
Riccardo De Carlis
 @DeCarlis_R
Aug 6

Right hemi-hepatectomy plus total caudate lobectomy for perihilar #cholangiocarcinoma

DeCarlis_R's tweet image. Right hemi-hepatectomy plus total caudate lobectomy for perihilar #cholangiocarcinoma
1
1
24
2
1K
HPBEverestMD's profile picture. General/GI Surgery.MCh 🩺 Executive Member of Society of Surgeons of Nepal (2025-2027)🇳🇵
Uttam Laudari
 @HPBEverestMD
Oct 30

💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery

HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
0
6
7
0
6K
MathurAmitK's profile picture. Transplant/HB Surgeon/Professor @MayoClinic | Interests: Transplant Practice, Research, Quality, Policy, Education | @nldac_asts | @UF @UMichSurgery Alum
Amit K. Mathur, MD MS FACS
@MathurAmitK
Dec 14

Getting ready to start some Saturday learning with INEDSYS Hepatology club on LT and #cholangiocarcinoma @inedsys …great stuff on YouTube as well. The global perspective is pretty impressive!

MathurAmitK's tweet image. Getting ready to start some Saturday learning with INEDSYS Hepatology club on LT and #cholangiocarcinoma @inedsys …great stuff on YouTube as well. The global perspective is pretty impressive!
3
0
26
0
904
malkadav's profile picture. GI oncologist, MD, PhD (FRA)
David Malka
 @malkadav
Apr 10

Interested in precision medicine and #BTC #cholangiocarcinoma? Read our paper @ESMO_Open! authors.elsevier.com/sd/article/S20…

malkadav's tweet image. Interested in precision medicine and #BTC #cholangiocarcinoma? Read our paper @ESMO_Open! authors.elsevier.com/sd/article/S20…
2
19
54
18
6K
curecc's profile picture. Our mission is to find a cure and improve the quality of life for cholangiocarcinoma patients. #CCAhope
Cholangiocarcinoma Foundation
@curecc
Jul 5

A CCA survivor thriver, his wife & his oncologist, Dr. Katie Kelley, just climbed to the top of Salesforce Tower 💪 She’s a CCF Innovation Grant recipient & Mark R. Clements Awardee—and a true partner in the climb toward a cure. #Cholangiocarcinoma #LivingBeyondDiagnosis…

curecc's tweet image. A CCA survivor thriver, his wife & his oncologist, Dr. Katie Kelley, just climbed to the top of Salesforce Tower 💪 She’s a CCF Innovation Grant recipient & Mark R. Clements Awardee—and a true partner in the climb toward a cure. #Cholangiocarcinoma #LivingBeyondDiagnosis…
0
2
19
0
542
boulter_lab's profile picture. Cancer Research UK funded group @MRC_HGU: liver cancer, signalling, lifting, ductular development and repair, gene editing and diversity in STEM.
Liver Growth and Cancer Lab
 @boulter_lab
Apr 17, 2024

Starting the inaugural basic science track @curecc a real pleasure to be part of this exciting group of researchers. #cholangiocarcinoma

boulter_lab's tweet image. Starting the inaugural basic science track @curecc a real pleasure to be part of this exciting group of researchers. #cholangiocarcinoma
0
6
22
1
1K
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Nov 3

🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy

HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
0
1
2
1
648
HelenMorement's profile picture. Helen Morement, DSc (hc), CEO of @CharityAMMF. At the heart of AMMF is #OurCCAFamily – every person diagnosed with #cholangiocarcinoma and their loved ones.
Helen Morement
 @HelenMorement
Feb 26

Today's the day! #AMMF is heading to Westminster to ask for a #FairerDealFaster for all with #cholangiocarcinoma! @charityammf

HelenMorement's tweet image. Today's the day! #AMMF is heading to Westminster to ask for a #FairerDealFaster for all with #cholangiocarcinoma! @charityammf
1
6
17
0
480
FlavioRochaMD's profile picture. Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute 🇺🇸 🇧🇷 in #PDX #PNW 🏔️ 🌲 🌊 ASCO FCOI: https://t.co/8W15jPkVs7
Flavio G Rocha, MD, FACS, FSSO
 @FlavioRochaMD
Oct 13

Phenomenal 🤩 Surgery Grand Rounds this am by Visiting Professor @Majeldoyle @WashU on rapidly evolving role of #transplantoncology for cancer #HCC #cholangiocarcinoma #CRLM 🔑 takeaways: 1) Patient selection 🧬 2) Treatment sequence/#HAI ⛽️ 3) Organ availability/allocation

FlavioRochaMD's tweet image. Phenomenal 🤩 Surgery Grand Rounds this am by Visiting Professor @Majeldoyle @WashU on rapidly evolving role of #transplantoncology for cancer #HCC #cholangiocarcinoma #CRLM 🔑 takeaways: 1) Patient selection 🧬 2) Treatment sequence/#HAI ⛽️ 3) Organ availability/allocation
FlavioRochaMD's tweet image. Phenomenal 🤩 Surgery Grand Rounds this am by Visiting Professor @Majeldoyle @WashU on rapidly evolving role of #transplantoncology for cancer #HCC #cholangiocarcinoma #CRLM 🔑 takeaways: 1) Patient selection 🧬 2) Treatment sequence/#HAI ⛽️ 3) Organ availability/allocation
FlavioRochaMD's tweet image. Phenomenal 🤩 Surgery Grand Rounds this am by Visiting Professor @Majeldoyle @WashU on rapidly evolving role of #transplantoncology for cancer #HCC #cholangiocarcinoma #CRLM 🔑 takeaways: 1) Patient selection 🧬 2) Treatment sequence/#HAI ⛽️ 3) Organ availability/allocation
0
2
22
0
1K
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Oct 31

🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]

HepatomaRes's tweet image. 🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]
0
2
4
1
910
HelenMorement's profile picture. Helen Morement, DSc (hc), CEO of @CharityAMMF. At the heart of AMMF is #OurCCAFamily – every person diagnosed with #cholangiocarcinoma and their loved ones.
Helen Morement
 @HelenMorement
May 6

All set and ready this evening to welcome everyone to #AMMF's European #Cholangiocarcinoma Conference starting tomorrow. Looking forward to the next 3 days!! #AMMF2025

HelenMorement's tweet image. All set and ready this evening to welcome everyone to #AMMF's European #Cholangiocarcinoma Conference starting tomorrow. Looking forward to the next 3 days!! #AMMF2025
0
4
20
1
420
ccaukgroup's profile picture. We are a BASL Special Interest Group whose purpose is to facilitate collaborative research, enhance service development and raise awareness of CCA.
ccauk
 @ccaukgroup
Feb 2, 2024

The 2024 #Cholangiocarcinoma-UK National meeting has just started! Join us! @CharityAMMF @basl_events Excellent programme, co-chairs Prof Shahid Khan & Sheela Jayaraman. Sponsors @Incyte @Servier

ccaukgroup's tweet image. The 2024 #Cholangiocarcinoma-UK National meeting has just started! Join us! @CharityAMMF @basl_events Excellent programme, co-chairs Prof Shahid Khan & Sheela Jayaraman. Sponsors @Incyte @Servier
2
6
15
0
1K
staclinds's profile picture. CEO and Founder of the Cholangiocarcinoma Foundation, mother of 5, happily married.
Stacie Lindsey
 @staclinds
8 h

This #NationalFamilyCaregiversMonth, we honor those walking beside loved ones with cholangiocarcinoma—offering comfort, learning, and spreading hope. 💚 Watch Cynthia’s heartfelt tribute to the caregivers who make this journey possible. 🎥 #Cholangiocarcinoma #Caregivers

0
0
0
0
35
CharityAMMF's profile picture. AMMF is the UK's only cholangiocarcinoma (bile duct cancer) charity. Working throughout the UK and Europe, and collaborating globally.
AMMF
 @CharityAMMF
17 h

💜SAVE THE DATE – REGISTRATION OPENING SOON💜 #AMMF’s 2026 European #Cholangiocarcinoma Conference: 📅 13–15 May 2026 at the 📍Radisson Blu Hotel, Stansted, UK Stay tuned, registration will be launching soon! #bileductcancer #AMMFConference2026 #CCA

CharityAMMF's tweet image. 💜SAVE THE DATE – REGISTRATION OPENING SOON💜 #AMMF’s 2026 European #Cholangiocarcinoma Conference: 📅 13–15 May 2026 at the 📍Radisson Blu Hotel, Stansted, UK Stay tuned, registration will be launching soon! #bileductcancer #AMMFConference2026 #CCA
0
0
0
0
37
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Nov 5

👏 This paper uncovers how altered #glucose metabolism fuels #cholangiocarcinoma growth and explores metabolic vulnerabilities as promising therapeutic targets. From: Dr. Charupong Saengboonmee @ASingkarin @DrSabha @DrTravisBrown @PaulJBrindley @Chillslincoln79 @DanielJDrucker

HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Nov 5

🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer

HepatomaRes's tweet image. 🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer
HepatomaRes's tweet image. 🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer
HepatomaRes's tweet image. 🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer
HepatomaRes's tweet image. 🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer
0
0
1
0
320
0
0
1
0
186
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Nov 5

🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer

HepatomaRes's tweet image. 🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer
HepatomaRes's tweet image. 🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer
HepatomaRes's tweet image. 🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer
HepatomaRes's tweet image. 🍬 Glucose Addiction in #Cholangiocarcinoma: Opportunities for Therapeutic Development 🔥 Metabolic reprogramming driving CCA progression 🔥 Targeting glucose dependency for treatment 🔥 Translational insights for metabolic therapy 🔗 [oaepublish.com/articles/2394-…] #BileDuctCancer
0
0
1
0
320
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Nov 4

🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]

HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
0
5
24
7
2K
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Nov 3

🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy

HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
0
1
2
1
648
FlavioRochaMD's profile picture. Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute 🇺🇸 🇧🇷 in #PDX #PNW 🏔️ 🌲 🌊 ASCO FCOI: https://t.co/8W15jPkVs7
Flavio G Rocha, MD, FACS, FSSO
 @FlavioRochaMD
Nov 1

Please consider applying to this great program if interested in #cholangiocarcinoma globally 🌎 #mentorship #payitforward #nextgeneration

staclinds's profile picture. CEO and Founder of the Cholangiocarcinoma Foundation, mother of 5, happily married.
Stacie Lindsey
 @staclinds
Oct 31

📢 Deadline Extension: The Precision-BTC-Network, in collaboration with ENS-CCA and @curecc's International Cholangiocarcinoma Research Network, invites applications for its Mentorship Program. NEW application deadline: November 7 🌐lnkd.in/d6aFK_DA

0
1
4
0
3K
0
0
9
1
2K
Springer_Med's profile picture. Trustworthy, tailored, cutting-edge content for medical professionals who want to deliver the best possible care. #EdsChoice selections by the content team.
Springer Medicine
 @Springer_Med
Nov 1

Unfortunately only 15–25% of patients with #cholangiocarcinoma qualify for second-line therapy. But what are the current treatment options for these patients, what therapies are on the horizon, and can biomarkers help to improve outcomes? 👉 buff.ly/Ow5YL6A #OncTwitter

0
0
0
0
67
VautheyMD's profile picture.
Jean-Nicolas Vauthey MD
 @VautheyMD
Oct 31

Important feature #intrahepatic #cholangiocarcinoma = desmoplastic reaction. May extend beyond the tumor in portal triads, hepatic hilum and extrahepatically along hepatic veins. Increased duration and difficulty of surgery!👇 #oncsurgery @SSATNews @AHPBA @IHPBA

HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Oct 27

👏 This paper investigates the diverse roles of collagen molecules in #intrahepatic #cholangiocarcinoma, revealing their impact on tumor growth, invasion, and remodeling of the extracellular matrix. @DrNguyenhiep @timnewhook19 @HalletJulie @FlavioRochaMD @skmaithel @VautheyMD

0
1
8
3
2K
0
3
13
3
1K
CharityAMMF's profile picture. AMMF is the UK's only cholangiocarcinoma (bile duct cancer) charity. Working throughout the UK and Europe, and collaborating globally.
AMMF
 @CharityAMMF
Oct 31

Yesterday, the Scottish Parliament debated #cholangiocarcinoma awareness for #LiverCancerAwarenessMonth. You can read a summary of the debate and watch the recording on the AMMF website: ammf.org.uk/2025/10/31/sco…

CharityAMMF's tweet image. Yesterday, the Scottish Parliament debated #cholangiocarcinoma awareness for #LiverCancerAwarenessMonth. You can read a summary of the debate and watch the recording on the AMMF website: ammf.org.uk/2025/10/31/sco…
0
2
6
0
88
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Oct 31

🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]

HepatomaRes's tweet image. 🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]
0
2
4
1
910
CharityAMMF's profile picture. AMMF is the UK's only cholangiocarcinoma (bile duct cancer) charity. Working throughout the UK and Europe, and collaborating globally.
AMMF
 @CharityAMMF
Oct 30

At 5pm today, the Scottish Parliament will debate #cholangiocarcinoma awareness for #LiverCancerAwarenessMonth. You can watch the debate live online, or as an on-demand recording. 🔗 Watch now | scottishparliament.tv #RethinkLiverCancer #Scotland #debate

CharityAMMF's tweet image. At 5pm today, the Scottish Parliament will debate #cholangiocarcinoma awareness for #LiverCancerAwarenessMonth. You can watch the debate live online, or as an on-demand recording. 🔗 Watch now | scottishparliament.tv #RethinkLiverCancer #Scotland #debate
0
1
2
0
71
CurrentOncology's profile picture. Current Oncology (ISSN: 1718-7729, IF 3.4) is an international, scientific, peer reviewed, #openaccess journal published monthly by @MDPIopenaccess. #oncology
Current Oncology
 @CurrentOncology
Oct 30

📅 New #Review in #Vol32_Iss10 📑 "Neoadjuvant Strategies for Patients with Resectable Biliary Tract Cancers: A Review" ✍️ by Chelsea R. Olson et al. 📍 Access the full paper here: brnw.ch/21wX3yc #Cholangiocarcinoma #NeoadjuvantTherapy

0
0
0
0
35
HPBEverestMD's profile picture. General/GI Surgery.MCh 🩺 Executive Member of Society of Surgeons of Nepal (2025-2027)🇳🇵
Uttam Laudari
 @HPBEverestMD
Oct 30

💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery

HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
0
6
7
0
6K
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Oct 30

👏 This narrative review summarizes recent progress in liver #transplantation for #intrahepatic #cholangiocarcinoma, highlighting refined selection criteria, improved outcomes, and future directions in patient management. @CalderonNo81257 @frandesanti @TorzilliGuido @pashtoonkasi

HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Oct 30

🩹 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Latest Advances and Evolving Perspectives 🧬Refined transplant selection & outcomes 🧬 Integration of systemic and locoregional therapies 🧬 Redefining transplantation in iCCA management 🔗 [oaepublish.com/articles/2394-…]

HepatomaRes's tweet image. 🩹 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Latest Advances and Evolving Perspectives 🧬Refined transplant selection & outcomes 🧬 Integration of systemic and locoregional therapies 🧬 Redefining transplantation in iCCA management 🔗 [oaepublish.com/articles/2394-…]
0
0
3
0
336
0
1
3
0
236
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Oct 30

🩹 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Latest Advances and Evolving Perspectives 🧬Refined transplant selection & outcomes 🧬 Integration of systemic and locoregional therapies 🧬 Redefining transplantation in iCCA management 🔗 [oaepublish.com/articles/2394-…]

HepatomaRes's tweet image. 🩹 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Latest Advances and Evolving Perspectives 🧬Refined transplant selection & outcomes 🧬 Integration of systemic and locoregional therapies 🧬 Redefining transplantation in iCCA management 🔗 [oaepublish.com/articles/2394-…]
0
0
3
0
336
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Oct 30

🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma 💡 #Multimodal downstaging strategies 💡 Expanding surgical eligibility in #iCCA 💡 Toward better prognosis through tailored therapy 🔗 [oaepublish.com/articles/2394-…]

HepatomaRes's tweet image. 🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma 💡 #Multimodal downstaging strategies 💡 Expanding surgical eligibility in #iCCA 💡 Toward better prognosis through tailored therapy 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma 💡 #Multimodal downstaging strategies 💡 Expanding surgical eligibility in #iCCA 💡 Toward better prognosis through tailored therapy 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma 💡 #Multimodal downstaging strategies 💡 Expanding surgical eligibility in #iCCA 💡 Toward better prognosis through tailored therapy 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma 💡 #Multimodal downstaging strategies 💡 Expanding surgical eligibility in #iCCA 💡 Toward better prognosis through tailored therapy 🔗 [oaepublish.com/articles/2394-…]
0
1
3
0
550
GiOncNow's profile picture. GI Oncology Now brings you the latest research and updates in #livercancer, #coloncancer, #pancreaticcancer, and more in the gastrointestinal oncology sphere.
GI Oncology Now
 @GiOncNow
Oct 29

📺 Dr. Matthew Krebs of @OfficialUoM describes the rationale behind his study presented at #ESMO25 that explored the next-generation KRAS G12C inhibitor #divarasib in pancreatic cancer and #cholangiocarcinoma: buff.ly/bLYl8HE

0
0
0
0
85
BasGrootKoerkam's profile picture. HPB-transplant surgeon
Bas Groot Koerkamp
 @BasGrootKoerkam
Oct 3

Primary percutaneous stenting for malignant hilar biliary obstruction. No longer cholangitis or pancreatitis keeping you from systemic treatment. #cholangiocarcinoma #drainage authors.elsevier.com/sd/article/S25…

BasGrootKoerkam's tweet image. Primary percutaneous stenting for malignant hilar biliary obstruction. No longer cholangitis or pancreatitis keeping you from systemic treatment. #cholangiocarcinoma #drainage authors.elsevier.com/sd/article/S25…
1
16
42
11
4K
BeauToskichMD's profile picture. Professor of Radiology, Director of Interventional Oncology, Mayo Clinic Florida. Views are my own.
Beau Bosko Toskich, MD FSIR
@BeauToskichMD
Oct 24

Unresectable intrahepatic #cholangiocarcinoma conversion/transplantation is our #1 MDT mission. 🤝 This evidence is so welcome. ✨ Inadequate FLR, tumor response, and biological test-of-time are addressed with neoadjuvant #Y90 radiation lobectomy. 🌳 We are exploring this…

BeauToskichMD's tweet image. Unresectable intrahepatic #cholangiocarcinoma conversion/transplantation is our #1 MDT mission. 🤝 This evidence is so welcome. ✨ Inadequate FLR, tumor response, and biological test-of-time are addressed with neoadjuvant #Y90 radiation lobectomy. 🌳 We are exploring this…
BeauToskichMD's tweet image. Unresectable intrahepatic #cholangiocarcinoma conversion/transplantation is our #1 MDT mission. 🤝 This evidence is so welcome. ✨ Inadequate FLR, tumor response, and biological test-of-time are addressed with neoadjuvant #Y90 radiation lobectomy. 🌳 We are exploring this…
BeauToskichMD's tweet image. Unresectable intrahepatic #cholangiocarcinoma conversion/transplantation is our #1 MDT mission. 🤝 This evidence is so welcome. ✨ Inadequate FLR, tumor response, and biological test-of-time are addressed with neoadjuvant #Y90 radiation lobectomy. 🌳 We are exploring this…
FlavioRochaMD's profile picture. Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute 🇺🇸 🇧🇷 in #PDX #PNW 🏔️ 🌲 🌊 ASCO FCOI: https://t.co/8W15jPkVs7
Flavio G Rocha, MD, FACS, FSSO
 @FlavioRochaMD
Oct 24

Real world 🌎 #NEOGAP #cholangiocarcinoma @OHSUKnight @curecc @c3_cholangio 💚

0
3
16
1
5K
1
6
50
5
4K
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Nov 4

🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]

HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🩺 Liver Transplantation for Intrahepatic #Cholangiocarcinoma: Insights from the UK NHSBT Pilot Programme 🇬🇧 Evidence from a national pilot initiative 📊 Refined selection & transplant outcomes 💡 Expanding treatment frontiers in iCCA care 🔗 [oaepublish.com/articles/2394-…]
0
5
24
7
2K
curecc's profile picture. Our mission is to find a cure and improve the quality of life for cholangiocarcinoma patients. #CCAhope
Cholangiocarcinoma Foundation
@curecc
Oct 3

Kicking off the 7th Annual #Cholangiocarcinoma Summit in Scottsdale, AZ. 🌵 Together, we’re building knowledge, community, and hope.

curecc's tweet image. Kicking off the 7th Annual #Cholangiocarcinoma Summit in Scottsdale, AZ. 🌵 Together, we’re building knowledge, community, and hope.
curecc's tweet image. Kicking off the 7th Annual #Cholangiocarcinoma Summit in Scottsdale, AZ. 🌵 Together, we’re building knowledge, community, and hope.
curecc's tweet image. Kicking off the 7th Annual #Cholangiocarcinoma Summit in Scottsdale, AZ. 🌵 Together, we’re building knowledge, community, and hope.
curecc's tweet image. Kicking off the 7th Annual #Cholangiocarcinoma Summit in Scottsdale, AZ. 🌵 Together, we’re building knowledge, community, and hope.
0
7
26
0
3K
SewantiLimaye's profile picture. Director Medical&Precision Oncology #precisiononcology #liquidbx #hnc #LCSM @DanaFarber @Harvard @ColumbiaMed @JIPOEditors @rfhospital #IMPACTIndia
Sewanti Limaye 🇮🇳🇺🇸
 @SewantiLimaye
Dec 11

Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care

SewantiLimaye's tweet image. Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care
SewantiLimaye's tweet image. Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care
SewantiLimaye's tweet image. Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care
SewantiLimaye's tweet image. Privileged to present single center data #Cholangiocarcinoma #Gallbladder @RFhospital to @JavleMilind Thank you for gracing us with your presence and for the extended time you spent with us deliberating on case solutions and research propositions! @Soumilvyas @Jarurat_care
JavleMilind's profile picture. Hubert L and Olive Stringer Professor GI Medical Oncology and Attending Physician, MD Anderson Cancer Center Chair, NCI Task Force Hepatobiliary Cancers
Milind Javle
 @JavleMilind
Dec 10

Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas

JavleMilind's tweet image. Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas
JavleMilind's tweet image. Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas
JavleMilind's tweet image. Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas
JavleMilind's tweet image. Great work in #biliarycancers and #cholangiocarcinoma by Indian investigators @Jarurat_care @SewantiLimaye @curecc @SGoswamiMDPhD @saumilvyas
0
4
22
0
3K
0
2
15
0
731
Youssefmd96's profile picture. 🌱 IM PGY-2, ex-researcher future Gastroenterologist
Mohammed Youssef MD,
 @Youssefmd96
Apr 19, 2024

Glad to share that have I presented two abstracts at the CCF Conference! @curecc Thanks Dr. @LewisRobertsMD for the guidance and support. #CCFConference #cholangiocarcinoma

Youssefmd96's tweet image. Glad to share that have I presented two abstracts at the CCF Conference! @curecc Thanks Dr. @LewisRobertsMD for the guidance and support. #CCFConference #cholangiocarcinoma
Youssefmd96's tweet image. Glad to share that have I presented two abstracts at the CCF Conference! @curecc Thanks Dr. @LewisRobertsMD for the guidance and support. #CCFConference #cholangiocarcinoma
Youssefmd96's tweet image. Glad to share that have I presented two abstracts at the CCF Conference! @curecc Thanks Dr. @LewisRobertsMD for the guidance and support. #CCFConference #cholangiocarcinoma
2
5
60
3
6K
MarioBalsaMD's profile picture. Medical Oncology resident at @ICO_oncologia | Currently Rotation Resident Research at @MDAndersonNews 🇺🇸 | @OncoAlert team 💥 #OncoAlertAF | Pianist 🎹
Mario Balsa
@MarioBalsaMD
Oct 20

🚨#ESMO25 #Cholangiocarcinoma –Phase 2–3 ZSAB-neoGOLP trial (Toripalimab + Lenvatinib + GEMOX) in resectable high-risk iCCA 🎯 mEFS 18.0 vs 8.7 mo 💥 ORR 54.4% | MPR 19.3% | pCR 4.5% ✨ OS trend favoring neoadjuvant arm (NE vs 31.4 mo) A strong neoadjuvant signal! Sometimes the…

MarioBalsaMD's tweet image. 🚨#ESMO25 #Cholangiocarcinoma –Phase 2–3 ZSAB-neoGOLP trial (Toripalimab + Lenvatinib + GEMOX) in resectable high-risk iCCA 🎯 mEFS 18.0 vs 8.7 mo 💥 ORR 54.4% | MPR 19.3% | pCR 4.5% ✨ OS trend favoring neoadjuvant arm (NE vs 31.4 mo) A strong neoadjuvant signal! Sometimes the…
MarioBalsaMD's tweet image. 🚨#ESMO25 #Cholangiocarcinoma –Phase 2–3 ZSAB-neoGOLP trial (Toripalimab + Lenvatinib + GEMOX) in resectable high-risk iCCA 🎯 mEFS 18.0 vs 8.7 mo 💥 ORR 54.4% | MPR 19.3% | pCR 4.5% ✨ OS trend favoring neoadjuvant arm (NE vs 31.4 mo) A strong neoadjuvant signal! Sometimes the…
MarioBalsaMD's tweet image. 🚨#ESMO25 #Cholangiocarcinoma –Phase 2–3 ZSAB-neoGOLP trial (Toripalimab + Lenvatinib + GEMOX) in resectable high-risk iCCA 🎯 mEFS 18.0 vs 8.7 mo 💥 ORR 54.4% | MPR 19.3% | pCR 4.5% ✨ OS trend favoring neoadjuvant arm (NE vs 31.4 mo) A strong neoadjuvant signal! Sometimes the…
0
16
32
10
2K
HPBEverestMD's profile picture. General/GI Surgery.MCh 🩺 Executive Member of Society of Surgeons of Nepal (2025-2027)🇳🇵
Uttam Laudari
 @HPBEverestMD
Oct 30

💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery

HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
HPBEverestMD's tweet image. 💡 Takeaway: Integration of AI, molecular profiling & precision surgery is redefining ICC outcomes. 🌍 #APHPBA #HPBSurgery #Cholangiocarcinoma #SurgicalOncology #AIinSurgery
0
6
7
0
6K
Penn_IR's profile picture. #minimallyinvasive
PennIR
 @Penn_IR
Mar 5, 2023

Next up is @TerenceGade talking about biomarkers for #HCC and #Cholangiocarcinoma #SIR23PHX

Penn_IR's tweet image. Next up is @TerenceGade talking about biomarkers for #HCC and #Cholangiocarcinoma #SIR23PHX
0
4
18
0
2K
malkadav's profile picture. GI oncologist, MD, PhD (FRA)
David Malka
 @malkadav
Apr 10

Interested in precision medicine and #BTC #cholangiocarcinoma? Read our paper @ESMO_Open! authors.elsevier.com/sd/article/S20…

malkadav's tweet image. Interested in precision medicine and #BTC #cholangiocarcinoma? Read our paper @ESMO_Open! authors.elsevier.com/sd/article/S20…
2
19
54
18
6K
FlavioRochaMD's profile picture. Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute 🇺🇸 🇧🇷 in #PDX #PNW 🏔️ 🌲 🌊 ASCO FCOI: https://t.co/8W15jPkVs7
Flavio G Rocha, MD, FACS, FSSO
 @FlavioRochaMD
Oct 13

Phenomenal 🤩 Surgery Grand Rounds this am by Visiting Professor @Majeldoyle @WashU on rapidly evolving role of #transplantoncology for cancer #HCC #cholangiocarcinoma #CRLM 🔑 takeaways: 1) Patient selection 🧬 2) Treatment sequence/#HAI ⛽️ 3) Organ availability/allocation

FlavioRochaMD's tweet image. Phenomenal 🤩 Surgery Grand Rounds this am by Visiting Professor @Majeldoyle @WashU on rapidly evolving role of #transplantoncology for cancer #HCC #cholangiocarcinoma #CRLM 🔑 takeaways: 1) Patient selection 🧬 2) Treatment sequence/#HAI ⛽️ 3) Organ availability/allocation
FlavioRochaMD's tweet image. Phenomenal 🤩 Surgery Grand Rounds this am by Visiting Professor @Majeldoyle @WashU on rapidly evolving role of #transplantoncology for cancer #HCC #cholangiocarcinoma #CRLM 🔑 takeaways: 1) Patient selection 🧬 2) Treatment sequence/#HAI ⛽️ 3) Organ availability/allocation
FlavioRochaMD's tweet image. Phenomenal 🤩 Surgery Grand Rounds this am by Visiting Professor @Majeldoyle @WashU on rapidly evolving role of #transplantoncology for cancer #HCC #cholangiocarcinoma #CRLM 🔑 takeaways: 1) Patient selection 🧬 2) Treatment sequence/#HAI ⛽️ 3) Organ availability/allocation
0
2
22
0
1K
curecc's profile picture. Our mission is to find a cure and improve the quality of life for cholangiocarcinoma patients. #CCAhope
Cholangiocarcinoma Foundation
@curecc
Jul 5

A CCA survivor thriver, his wife & his oncologist, Dr. Katie Kelley, just climbed to the top of Salesforce Tower 💪 She’s a CCF Innovation Grant recipient & Mark R. Clements Awardee—and a true partner in the climb toward a cure. #Cholangiocarcinoma #LivingBeyondDiagnosis…

curecc's tweet image. A CCA survivor thriver, his wife & his oncologist, Dr. Katie Kelley, just climbed to the top of Salesforce Tower 💪 She’s a CCF Innovation Grant recipient & Mark R. Clements Awardee—and a true partner in the climb toward a cure. #Cholangiocarcinoma #LivingBeyondDiagnosis…
0
2
19
0
542
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Nov 3

🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy

HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
HepatomaRes's tweet image. 🎯 Challenges and Opportunities in Treating Intrahepatic #Cholangiocarcinoma: Targeted Therapy Perspectives 🧬 Precision oncology in #iCCA 🔍 Targeting driver mutations & pathways 💡 Expanding options for individualized care 🔗 [oaepublish.com/articles/2394-…] #TargetedTherapy
0
1
2
1
648
HepatomaRes's profile picture. A gold open-access journal, indexed in ESCI and Scopus, 2023 IF: 1.7. #livercancer #HCC #CCA #Hepatitis #liverdisease #livertwitter #MedEd #HCCtwitter
Hepatoma Research
 @HepatomaRes
Oct 31

🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]

HepatomaRes's tweet image. 🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]
HepatomaRes's tweet image. 🔪 Surgery for #HepatocellularCarcinoma and Intrahepatic #Cholangiocarcinoma: Two Decades of Milestone Changes 🏥 Evolution of surgical strategies 📊 Impact on prognosis and clinical practice 💡 Insights guiding future guideline updates 🔗 [oaepublish.com/articles/2394-…]
0
2
4
1
910
Journal_AHBPS's profile picture. This journal publishes original basic and clinical research on diseases of the liver, biliary system, and pancreas.
Annals of Hepato-Biliary-Pancreatic Surgery
 @Journal_AHBPS
Jun 13, 2023

Preoperative neutrophil-to-lymphocyte ratio is prognostic for early recurrence after curative intrahepatic cholangiocarcinoma resection 🌷doi.org/10.14701/ahbps… Ann Hepatobiliary Pancreat Surg 2023 May;27(2)Woo Jin Choi #Cholangiocarcinoma #Hepatectomy #Recurrence #Liver

Journal_AHBPS's tweet image. Preoperative neutrophil-to-lymphocyte ratio is prognostic for early recurrence after curative intrahepatic cholangiocarcinoma resection 🌷doi.org/10.14701/ahbps… Ann Hepatobiliary Pancreat Surg 2023 May;27(2)Woo Jin Choi #Cholangiocarcinoma #Hepatectomy #Recurrence #Liver
0
5
16
2
2K
FlavioRochaMD's profile picture. Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute 🇺🇸 🇧🇷 in #PDX #PNW 🏔️ 🌲 🌊 ASCO FCOI: https://t.co/8W15jPkVs7
Flavio G Rocha, MD, FACS, FSSO
 @FlavioRochaMD
Apr 11

Always bittersweet to leave @curecc #ccfac25 but feeling inspired with all the progress and future directions in #cholangiocarcinoma 💚 #onward #endcancer

FlavioRochaMD's tweet image. Always bittersweet to leave @curecc #ccfac25 but feeling inspired with all the progress and future directions in #cholangiocarcinoma 💚 #onward #endcancer
FlavioRochaMD's tweet image. Always bittersweet to leave @curecc #ccfac25 but feeling inspired with all the progress and future directions in #cholangiocarcinoma 💚 #onward #endcancer
FlavioRochaMD's tweet image. Always bittersweet to leave @curecc #ccfac25 but feeling inspired with all the progress and future directions in #cholangiocarcinoma 💚 #onward #endcancer
FlavioRochaMD's tweet image. Always bittersweet to leave @curecc #ccfac25 but feeling inspired with all the progress and future directions in #cholangiocarcinoma 💚 #onward #endcancer
0
5
34
0
2K
FlavioRochaMD's profile picture. Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute 🇺🇸 🇧🇷 in #PDX #PNW 🏔️ 🌲 🌊 ASCO FCOI: https://t.co/8W15jPkVs7
Flavio G Rocha, MD, FACS, FSSO
 @FlavioRochaMD
Jun 27

Getting ready to kick off @curecc @OHSUKnight PDX Regional #cholangiocarcinoma Symposium

FlavioRochaMD's tweet image. Getting ready to kick off @curecc @OHSUKnight PDX Regional #cholangiocarcinoma Symposium
FlavioRochaMD's tweet image. Getting ready to kick off @curecc @OHSUKnight PDX Regional #cholangiocarcinoma Symposium
FlavioRochaMD's tweet image. Getting ready to kick off @curecc @OHSUKnight PDX Regional #cholangiocarcinoma Symposium
FlavioRochaMD's tweet image. Getting ready to kick off @curecc @OHSUKnight PDX Regional #cholangiocarcinoma Symposium
0
5
9
0
696
gagan_brar24's profile picture. GI Medical Oncologist with a research focus in #BTC/#CRC @cityofhope
Gagan Brar
 @gagan_brar24
Oct 3

Great talk by friend, colleague and awesome surgeon @laleh_melstrom reviewing conversion to surgical resection in #cholangiocarcinoma at the CCA Summit 2025 @cityofhope @CityofHopeSurg @curecc

gagan_brar24's tweet image. Great talk by friend, colleague and awesome surgeon @laleh_melstrom reviewing conversion to surgical resection in #cholangiocarcinoma at the CCA Summit 2025 @cityofhope @CityofHopeSurg @curecc
1
10
27
1
3K
DeCarlis_R's profile picture. 🇮🇹 HPB & Transplant Surgeon (liver/kidney/pancreas). Laparoscopy & robot. DCD & machine perfusion. Fond of my job. Tweets are my own.
Riccardo De Carlis
 @DeCarlis_R
Aug 6

Right hemi-hepatectomy plus total caudate lobectomy for perihilar #cholangiocarcinoma

DeCarlis_R's tweet image. Right hemi-hepatectomy plus total caudate lobectomy for perihilar #cholangiocarcinoma
1
1
24
2
1K

Something went wrong.


Something went wrong.


United States Trends